OPKO Health, Inc. (OPK)
USD 1.45
(-5.56%)
USD 1.45
(-5.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 622.47 Million USD | 2.77% |
| 2022 | 605.7 Million USD | -15.24% |
| 2021 | 714.6 Million USD | -10.84% |
| 2020 | 801.5 Million USD | 15.41% |
| 2019 | 694.5 Million USD | 5.26% |
| 2018 | 659.8 Million USD | -11.59% |
| 2017 | 746.33 Million USD | 10.6% |
| 2016 | 674.8 Million USD | -17.69% |
| 2015 | 819.8 Million USD | 89.81% |
| 2014 | 431.9 Million USD | -16.71% |
| 2013 | 518.53 Million USD | 499.12% |
| 2012 | 86.55 Million USD | 26.15% |
| 2011 | 68.6 Million USD | 25.21% |
| 2010 | 54.79 Million USD | 84.47% |
| 2009 | 29.7 Million USD | 38.77% |
| 2008 | 21.4 Million USD | -6.05% |
| 2007 | 22.78 Million USD | 3280.42% |
| 2006 | 674 Thousand USD | 143.32% |
| 2005 | 277 Thousand USD | 15.9% |
| 2004 | 239 Thousand USD | -76.97% |
| 2003 | 1.03 Million USD | -27.97% |
| 2002 | 1.44 Million USD | -4.19% |
| 2001 | 1.5 Million USD | -6.18% |
| 2000 | 1.6 Million USD | -15.59% |
| 1999 | 1.89 Million USD | 18.69% |
| 1998 | 1.6 Million USD | -5.88% |
| 1997 | 1.7 Million USD | 6.25% |
| 1996 | 1.6 Million USD | 6.67% |
| 1995 | 1.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 721.2 Million USD | 15.86% |
| 2024 Q2 | 584.55 Million USD | -18.95% |
| 2023 Q2 | 623.55 Million USD | 0.93% |
| 2023 Q1 | 617.8 Million USD | 2.0% |
| 2023 Q4 | 622.47 Million USD | 1.7% |
| 2023 Q3 | 612.1 Million USD | -1.84% |
| 2023 FY | 622.47 Million USD | 2.77% |
| 2022 Q2 | 650.8 Million USD | -5.95% |
| 2022 FY | 605.7 Million USD | -15.24% |
| 2022 Q3 | 595.71 Million USD | -8.46% |
| 2022 Q4 | 605.7 Million USD | 1.68% |
| 2022 Q1 | 691.97 Million USD | -3.17% |
| 2021 FY | 714.6 Million USD | -10.84% |
| 2021 Q1 | 823.06 Million USD | 2.69% |
| 2021 Q2 | 679.06 Million USD | -17.5% |
| 2021 Q3 | 652.07 Million USD | -3.98% |
| 2021 Q4 | 714.6 Million USD | 9.59% |
| 2020 Q4 | 801.5 Million USD | 7.22% |
| 2020 Q3 | 747.52 Million USD | 1.65% |
| 2020 Q2 | 735.39 Million USD | 7.53% |
| 2020 Q1 | 683.92 Million USD | -1.52% |
| 2020 FY | 801.5 Million USD | 15.41% |
| 2019 Q3 | 727.58 Million USD | -2.64% |
| 2019 FY | 694.5 Million USD | 5.26% |
| 2019 Q2 | 747.29 Million USD | -8.04% |
| 2019 Q1 | 812.6 Million USD | 23.16% |
| 2019 Q4 | 694.5 Million USD | -4.55% |
| 2018 Q3 | 692.35 Million USD | -3.9% |
| 2018 FY | 659.8 Million USD | -11.59% |
| 2018 Q4 | 659.8 Million USD | -4.7% |
| 2018 Q2 | 720.45 Million USD | -4.65% |
| 2018 Q1 | 755.6 Million USD | 1.24% |
| 2017 Q4 | 746.33 Million USD | 17.91% |
| 2017 FY | 746.33 Million USD | 10.6% |
| 2017 Q1 | 653.09 Million USD | -3.22% |
| 2017 Q2 | 661.86 Million USD | 1.34% |
| 2017 Q3 | 632.95 Million USD | -4.37% |
| 2016 Q1 | 795.33 Million USD | -2.98% |
| 2016 FY | 674.8 Million USD | -17.69% |
| 2016 Q4 | 674.8 Million USD | -2.85% |
| 2016 Q3 | 694.6 Million USD | -8.41% |
| 2016 Q2 | 758.38 Million USD | -4.65% |
| 2015 Q4 | 819.8 Million USD | -21.66% |
| 2015 Q2 | 698.5 Million USD | -0.17% |
| 2015 FY | 819.8 Million USD | 89.81% |
| 2015 Q1 | 699.67 Million USD | 62.0% |
| 2015 Q3 | 1.04 Billion USD | 49.82% |
| 2014 Q4 | 431.9 Million USD | 5.88% |
| 2014 Q1 | 524.44 Million USD | 1.14% |
| 2014 FY | 431.9 Million USD | -16.71% |
| 2014 Q2 | 414.25 Million USD | -21.01% |
| 2014 Q3 | 407.89 Million USD | -1.54% |
| 2013 Q2 | 328.59 Million USD | -1.66% |
| 2013 FY | 518.53 Million USD | 499.12% |
| 2013 Q4 | 518.53 Million USD | 0.68% |
| 2013 Q3 | 515.05 Million USD | 56.74% |
| 2013 Q1 | 334.15 Million USD | 286.09% |
| 2012 Q3 | 103.75 Million USD | 31.39% |
| 2012 Q4 | 86.55 Million USD | -16.58% |
| 2012 Q1 | 76.59 Million USD | 11.64% |
| 2012 FY | 86.55 Million USD | 26.15% |
| 2012 Q2 | 78.96 Million USD | 3.11% |
| 2011 Q3 | 48.52 Million USD | -1.49% |
| 2011 Q1 | 52.69 Million USD | -3.83% |
| 2011 FY | 68.6 Million USD | 25.21% |
| 2011 Q4 | 68.6 Million USD | 41.39% |
| 2011 Q2 | 49.25 Million USD | -6.53% |
| 2010 Q1 | 31.05 Million USD | 4.57% |
| 2010 FY | 54.79 Million USD | 84.47% |
| 2010 Q4 | 54.79 Million USD | 14.88% |
| 2010 Q3 | 47.69 Million USD | 165.54% |
| 2010 Q2 | 17.96 Million USD | -42.17% |
| 2009 FY | 29.7 Million USD | 38.77% |
| 2009 Q1 | 26.91 Million USD | 25.73% |
| 2009 Q3 | 19.25 Million USD | -7.4% |
| 2009 Q4 | 29.7 Million USD | 54.25% |
| 2009 Q2 | 20.79 Million USD | -22.73% |
| 2008 Q1 | 22.02 Million USD | -3.34% |
| 2008 Q3 | 20.83 Million USD | 3.13% |
| 2008 Q4 | 21.4 Million USD | 2.74% |
| 2008 FY | 21.4 Million USD | -6.05% |
| 2008 Q2 | 20.2 Million USD | -8.28% |
| 2007 Q2 | 10.12 Million USD | -5.67% |
| 2007 Q3 | 14.04 Million USD | 38.72% |
| 2007 Q1 | 10.73 Million USD | 1492.73% |
| 2007 Q4 | 22.78 Million USD | 62.2% |
| 2007 FY | 22.78 Million USD | 3280.42% |
| 2006 Q2 | 262 Thousand USD | -13.82% |
| 2006 Q4 | 674 Thousand USD | 76.44% |
| 2006 FY | 674 Thousand USD | 143.32% |
| 2006 Q1 | 304 Thousand USD | 9.75% |
| 2006 Q3 | 382 Thousand USD | 45.8% |
| 2005 Q2 | 160 Thousand USD | -16.67% |
| 2005 Q4 | 277 Thousand USD | 1159.09% |
| 2005 Q3 | 22 Thousand USD | -86.25% |
| 2005 FY | 277 Thousand USD | 15.9% |
| 2005 Q1 | 192 Thousand USD | -19.67% |
| 2004 Q4 | 239 Thousand USD | -8.08% |
| 2004 FY | 239 Thousand USD | -76.97% |
| 2004 Q1 | 383 Thousand USD | -63.1% |
| 2004 Q2 | 230 Thousand USD | -39.95% |
| 2004 Q3 | 260 Thousand USD | 13.04% |
| 2003 Q1 | 860 Thousand USD | -40.32% |
| 2003 Q2 | 966 Thousand USD | 12.33% |
| 2003 Q3 | 684 Thousand USD | -29.19% |
| 2003 Q4 | 1.03 Million USD | 51.75% |
| 2003 FY | 1.03 Million USD | -27.97% |
| 2002 Q2 | 1.06 Million USD | -24.13% |
| 2002 Q3 | 1.04 Million USD | -2.16% |
| 2002 Q4 | 1.44 Million USD | 38.16% |
| 2002 FY | 1.44 Million USD | -4.19% |
| 2002 Q1 | 1.4 Million USD | -6.58% |
| 2001 Q3 | 3.83 Million USD | 77.14% |
| 2001 Q4 | 1.5 Million USD | -60.78% |
| 2001 FY | 1.5 Million USD | -6.18% |
| 2001 Q1 | 2.17 Million USD | 35.68% |
| 2001 Q2 | 2.16 Million USD | -0.46% |
| 2000 FY | 1.6 Million USD | -15.59% |
| 2000 Q4 | 1.6 Million USD | -4.98% |
| 2000 Q3 | 1.68 Million USD | -2.43% |
| 2000 Q2 | 1.72 Million USD | -17.51% |
| 2000 Q1 | 2.09 Million USD | 10.37% |
| 1999 Q4 | 1.89 Million USD | -5.05% |
| 1999 FY | 1.89 Million USD | 18.69% |
| 1999 Q2 | 1.6 Million USD | -20.0% |
| 1999 Q1 | 2 Million USD | 25.0% |
| 1999 Q3 | 2 Million USD | 25.0% |
| 1998 FY | 1.6 Million USD | -5.88% |
| 1998 Q4 | 1.6 Million USD | -15.79% |
| 1998 Q2 | 2.4 Million USD | 41.18% |
| 1998 Q3 | 1.9 Million USD | -20.83% |
| 1998 Q1 | 1.7 Million USD | 0.0% |
| 1997 Q2 | 1.5 Million USD | -6.25% |
| 1997 Q4 | 1.7 Million USD | 13.33% |
| 1997 Q3 | 1.5 Million USD | 0.0% |
| 1997 FY | 1.7 Million USD | 6.25% |
| 1997 Q1 | 1.6 Million USD | 0.0% |
| 1996 Q1 | 1.5 Million USD | 0.0% |
| 1996 Q2 | 1.7 Million USD | 13.33% |
| 1996 FY | 1.6 Million USD | 6.67% |
| 1996 Q3 | 1.8 Million USD | 5.88% |
| 1996 Q4 | 1.6 Million USD | -11.11% |
| 1995 FY | 1.5 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1447.454% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -6990.412% |
| Aspira Women's Health Inc. | 8.62 Million USD | -7115.475% |
| Biodesix, Inc. | 94.51 Million USD | -558.596% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -35634.792% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -18391.506% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -18391.506% |
| Bionano Genomics, Inc. | 118.24 Million USD | -426.423% |
| CareDx, Inc | 223.28 Million USD | -178.78% |
| Check-Cap Ltd. | 1.33 Million USD | -46702.932% |
| Castle Biosciences, Inc. | 86.54 Million USD | -619.28% |
| DarioHealth Corp. | 38.24 Million USD | -1527.609% |
| Exact Sciences Corporation | 3.32 Billion USD | 81.285% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -345.191% |
| Guardant Health, Inc. | 1.62 Billion USD | 61.758% |
| ICON Public Limited Company | 7.74 Billion USD | 91.967% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 64.939% |
| Illumina, Inc. | 4.36 Billion USD | 85.743% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -11024.294% |
| iSpecimen Inc. | 6.07 Million USD | -10141.409% |
| Standard BioTools Inc. | 159.86 Million USD | -289.378% |
| MDxHealth SA | 121.92 Million USD | -410.547% |
| 23andMe Holding Co. | 206.64 Million USD | -201.228% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 43.302% |
| Myriad Genetics, Inc. | 312.9 Million USD | -98.939% |
| Mainz Biomed B.V. | 12.15 Million USD | -5019.154% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -56739.248% |
| NeoGenomics, Inc. | 739.69 Million USD | 15.846% |
| Neogen Corporation | 1.44 Billion USD | 56.773% |
| Inotiv, Inc. | 588.04 Million USD | -5.857% |
| Natera, Inc. | 691.79 Million USD | 10.02% |
| OpGen, Inc. | 13.44 Million USD | -4530.211% |
| Psychemedics Corporation | 6.59 Million USD | -9334.359% |
| Prenetics Global Limited | 44.01 Million USD | -1314.299% |
| Prenetics Global Limited | 44.01 Million USD | -1314.299% |
| Precipio, Inc. | 3.67 Million USD | -16852.042% |
| Personalis, Inc. | 95.65 Million USD | -550.734% |
| RadNet, Inc. | 2.07 Billion USD | 69.977% |
| Sera Prognostics, Inc. | 25.28 Million USD | -2362.046% |
| Sotera Health Company | 2.68 Billion USD | 76.831% |
| Neuronetics, Inc. | 81.64 Million USD | -662.459% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -2771.875% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -2771.875% |
| Trinity Biotech plc | 83.38 Million USD | -646.521% |
| T2 Biosystems, Inc. | 62.83 Million USD | -890.688% |
| Twist Bioscience Corporation | 152.97 Million USD | -306.926% |
| Exagen Inc. | 34.25 Million USD | -1717.457% |